Nature Reviews Cancer contents March 2015 Volume 15 Number 3 pp131-194

If you are unable to see the message below, click here to view.

Advertisement
New! Superior clone for CRISPR/Cas9 monoclonal antibody Diagenode now offers: New CRISPR/Cas9 clone 4G10 shows markedly superior performance compared to any other CRISPR/Cas9 antibody Validated for immunoblot, immunoprecipitation, and IF Recognizes Cas9 and dCas9 Learn more and get early access
TABLE OF CONTENTS
March 2015 Volume 15 Number 3
Impact Factor 37.912 *	In this issue Comment Research Highlights Reviews Correspondence Analysis Perspectives Also this month Article series: Clinical insights  Featured article: Milestones of Lynch syndrome: 1895–2015 Henry T. Lynch, Carrie L. Snyder, Trudy G. Shaw, Christopher D. Heinen & Megan P. Hitchins
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
nature.com webcasts Join us for our upcoming webcast with live Q&A: BioPharma Dealmakers: Drug Delivery Date: Wednesday, February 25, 2015 Time: 8AM PST, 11AM EST, 4PM GMT, 5PM CET Register for FREE Sponsored by: Polymer Factory, Pulmatrix, Phosphorex, Nanovelos
Article series: Clinical insights Comment: Understanding allergy and cancer risk: what are the barriers? Esther Hoste, Sara Cipolat & Fiona M. Watt p131 | doi:10.1038/nrc3909 Hoste et al. discuss whether allergic immune responses, which have been observed to be protective against some types of cancer, can be activated to target cancer, and what the mechanism of antitumour allergic responses might be. Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Metastasis: Feeding the beast p134 | doi:10.1038/nrc3913 Two studies have examined how manipulation of energy availability by cancer cells, mediated by changes in microRNAs (miRNAs), can fuel metastatic colonization. PDF Angiogenesis: A sudden rush of blood to the tumour p135 | doi:10.1038/nrc3914 This study describes a novel approach to increase blood vessels in tumours to enhance drug delivery, uptake and metabolism. PDF Tumorigenesis: Mutant relationships p135 | doi:10.1038/nrc3917 Stites and Trampont et al. used mathematical modelling with verification in cells and cancer genome data to understand the effects of weakly activating RAS mutations. They found that pairs of mutations within the RAS pathway might be able to act together to create a selective advantage in human tumours. PDF DNA repair: A new tool to target DNA repair p136 | doi:10.1038/nrc3919 Two studies have shown that DNA polymerase-&thgr; (POLQ) promotes an alternative form of non-homologous end-joining (alt-NHEJ) and suppresses homologous recombination (HR) in mammalian cells. The activity of alt-NHEJ is essential for the survival of cells deficient in HR. PDF IN BRIEF Breast cancer: The importance of recycling | Tumour heterogeneity: A free ride | Radiotherapy: Healing the brain | Therapeutics: Give it a shock PDF Cancer JOBS of the week Pediatric Cancer Reseracher University of Calgary Postdoc in Cancer Biology Baylor Collge of Medicine Head Bioinformatician for the Centre for Evolution and Cancer Closing Institute of Cancer Research (ICR) Postdoctoral Researcher Position in Cancer Biology University of Pennsylvania Postdoctoral Fellowship - Cancer Stem Cell Biology Cleveland Clinic Lerner Research Institute More Science jobs from Cancer EVENT 2nd International Symposium of the Cancer Research Center of Lyon (CRCL) 21.09.15 Lyon, France More science events from
REVIEWS		Top
Topoisomerase-mediated chromosomal break repair: an emerging player in many games Mohamed E. Ashour, Reham Atteya & Sherif F. El-Khamisy p137 | doi:10.1038/nrc3892 Protein-linked DNA breaks can be formed through the abortive activity of topoisomerases — this Review discusses the roles of such breaks during transcription and in triggering gene deletions and translocations in cancer. Abstract | Full Text | PDF
DNMT3A in haematological malignancies Liubin Yang, Rachel Rau & Margaret A. Goodell p152 | doi:10.1038/nrc3895 Mutations in the gene encoding DNA methyltransferase 3A (DNMT3A) have been reported in patients with various haematological malignancies, suggesting that DNMT3A could be a tumour suppressor. In this Review, Yang et al. put data from basic science studies into clinical context, opening stimulating discussions regarding possible new therapeutic avenues. Abstract | Full Text | PDF | Supplementary information
CORRESPONDENCE		Top
Correspondence: Integrative oncology — strong science is needed for better patient care Heather Greenlee et al. p165 | doi:10.1038/nrc3822-c1 Full Text | PDF
REPLY		Top
Reply: Integrative oncology — strong science is needed for better patient care David H. Gorski p165 | doi:10.1038/nrc3822-c2 Full Text | PDF
ANALYSIS		Top
Therapeutic opportunities within the DNA damage response Laurence H. Pearl et al. p166 | doi:10.1038/nrc3891 This Analysis uses the published literature to form a DNA damage response network and then uses this to identify potential synthetic lethal interactions and to assess the druggability of proteins in the DNA damage response network. Abstract | Full Text | PDF | Supplementary information
PERSPECTIVES		Top
TIMELINE Milestones of Lynch syndrome: 1895–2015 Henry T. Lynch et al. p181 | doi:10.1038/nrc3878 Lynch syndrome is caused by heterozygous mutations and epimutations in mismatch repair genes, which lead to specific pathologies, including increased risk of multiple types of cancer and microsatellite instability. Lynch syndrome has been pivotal to the history of understanding hereditary cancer-prone syndromes and continues to lead the way in our understanding of the risk and treatment of familial cancers. Abstract | Full Text | PDF
Advertisement
Animation: Targeting cancer cell metabolism This animation, created by Nature Reviews Drug Discovery, with distribution supported by Forma Therapeutics, explores the key aspects of the altered metabolism in cancer cells and explains how these can be exploited for the development of new anticancer strategies.  Access the animation free online. Produced with support from: Forma Therapeutics, Inc.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.